Gwynn Long is an Oncology physician affiliated with Duke University. OpenAlex indexes 141 publications with 3,271 citations (h-index 28); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2100 Erwin Rd
Durham, NC 277100001
Telephone
919-620-4467Registry record last updated 18 Aug 2013.
Clinical trials
- ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN
Sponsor: Gwynn Long, M.D.
- Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma
Sponsor: Cristina Gasparetto
- Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma
Sponsor: Duke University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Incyte CorporationProgram year20231 payment
- Takeda Pharmaceuticals U.S.A., Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
67.6%Thalidomide Analog54.9%Lenalidomide58%Revlimid26%Pomalyst17%Part D≥27 patientsProteasome Inhibitor4.4%Ninlaro100%Part D<11 patients+ 2 more classes in this area
Dermatology
13.2%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor13.2%Acyclovir100%Part D≥14 patientsNervous system
10.7%Phenothiazine3.8%Prochlorperazine Maleate100%Part D<11 patientsOpioid Agonist3.6%Oxycodone Hcl100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Geriatric Assessment Reveals Actionable Impairments in Hematopoietic Stem Cell Transplantation Candidates Age 18 to 80 Years
Biology of Blood and Marrow Transplantation
2022 - A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease
Biology of Blood and Marrow Transplantation
2022 - Home-Based Hematopoietic Cell Transplantation in the United States
Biology of Blood and Marrow Transplantation
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Pamela Douglas, MD
Duke University
Adrian Hernandez, MD
Duke University
Scott Antonia, MD
Duke University
Jonathan Piccini, MD
Duke University
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”